Investors
OPTIMIZED BY EVOLUTION
Wugen is developing off-the-shelf cellular therapies for cancer
Our cell therapy products originate from healthy donors and are optimized to enhance their anti-tumor function.
![](https://wugen.com/wp-content/uploads/2021/06/RiverVest-Logo-Preferred-300x58.jpg)
![](https://wugen.com/wp-content/uploads/2021/01/LYZZ.png)
![](https://wugen.com/wp-content/uploads/2021/06/Biogenerator-Logo-1024x234.jpg)
![](https://wugen.com/wp-content/uploads/2021/06/Abingowrth-Logo-1-1.png)
![](https://wugen.com/wp-content/uploads/2021/07/tybourne-1.png)
![](https://wugen.com/wp-content/uploads/2021/06/ICG-Logo-1-1024x446.png)
![](https://wugen.com/wp-content/uploads/2021/06/Aisling-Capital-Logo-1-1.png)
![](https://wugen.com/wp-content/uploads/2022/01/Screen-Shot-2022-01-27-at-10.49.06-1.png)
![](https://wugen.com/wp-content/uploads/2021/07/Alexandria-Ventures-300x55.png)
![](https://wugen.com/wp-content/uploads/2021/07/Sands-Capital-Logo-rgb-1.png)
- Abingworth Bioventures
- Aisling Capital
- Alexandria Venture Investments
- BioGenerator
- Alpha Wave
- Fidelity Management & Research Company, LLC
- Intermediate Capital Group (ICG)
- Lightchain Capital
- LYZZ Capital
- RiverVest Ventures
- Sands Capital
- Tybourne Capital Management
- Velosity Capital Management
Next in our story
Copyright © 2024 Wugen. All Rights Reserved.
a COGNEO design